Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Singer

Showing results (571-580 of 666) with videos related to

Pageof 67
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 1, 1996
Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthinesK J Russell, L W Wiens, G W Demers, et al.
Blood|April 1, 1993
Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignanciesS N Rabinowe, D Neuberg, P J Bierman, et al.
Cancer|June 18, 2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohortTomasz P Srokowski, James E Liebmann, Manuel R Modiano, et al.
The New England Journal of Medicine|June 20, 1991
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancerJ Nemunaitis, S N Rabinowe, J W Singer, et al.
The New England Journal of Medicine|August 20, 1987
Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemiaP J Fialkow, J W Singer, W H Raskind, et al.
British Journal of Haematology|December 28, 2019
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2016
Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic LeukemiaAvery Polk, Ye Lu, Tianjiao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomasJohn M Pagel, Christian Laugen, Lynn Bonham, et al.
Plos One|November 9, 2013
Discovery of microorganisms and enzymes involved in high-solids decomposition of rice straw using metagenomic analysesAmitha P Reddy, Christopher W Simmons, Patrik D'haeseleer, et al.
British Journal of Haematology|April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trialRuth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Pageof 67

Showing results (571-580 of 666) with videos related to

Sort By:
Pageof 67
International Journal of Radiation Oncology, Biology, Physics|December 1, 1996
Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthinesK J Russell, L W Wiens, G W Demers, et al.
Blood|April 1, 1993
Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignanciesS N Rabinowe, D Neuberg, P J Bierman, et al.
Cancer|June 18, 2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohortTomasz P Srokowski, James E Liebmann, Manuel R Modiano, et al.
The New England Journal of Medicine|June 20, 1991
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancerJ Nemunaitis, S N Rabinowe, J W Singer, et al.
The New England Journal of Medicine|August 20, 1987
Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemiaP J Fialkow, J W Singer, W H Raskind, et al.
British Journal of Haematology|December 28, 2019
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)Ruth Pettengell, Monika Długosz-Danecka, David Andorsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2016
Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic LeukemiaAvery Polk, Ye Lu, Tianjiao Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomasJohn M Pagel, Christian Laugen, Lynn Bonham, et al.
Plos One|November 9, 2013
Discovery of microorganisms and enzymes involved in high-solids decomposition of rice straw using metagenomic analysesAmitha P Reddy, Christopher W Simmons, Patrik D'haeseleer, et al.
British Journal of Haematology|April 28, 2016
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trialRuth Pettengell, Catherine Sebban, Pier Luigi Zinzani, et al.
Pageof 67